Supply Disruption Alert: Emerade 500 microgram and 300 microgram adrenaline auto-injector devices

Supply Disruption Alert: Emerade 500 microgram and 300 microgram adrenaline auto-injector devices

September 25, 2019

Emerade 500 microgram and 300 microgram devices, manufactured by Bausch & Lomb UK, are experiencing a short-term disruption in supply:

Emerade 500 microgram – expected w/c 23rd September 2019
Emerade 300 microgram – out of stock until early October 2019

The Supply Disruption Alert (SDA/2019/004) issued by DHSC states

‘In the UK there are two alternative AAI devices available, EpiPen, supplied by Mylan and Jext, supplied by ALK. However, neither of these companies supply a 500 microgram strength AAI. Both companies manufacture 300 microgram AAI pens. Both companies are aware of the supply disruptions affecting Emerade 500microgram and 300 microgram AAIs.

Both Jext and EpiPen AAIs are currently available, however, supplies of Jext are unlikely to be sufficient to support a significant switch to this product and therefore where there is no patient / clinician preference EpiPen should be considered as the first line alternative.

The advice from national experts is, in the absence of Emerade 500 microgram, affected patients should be prescribed 300 microgram AAIs and advised to keep at least two pens with them at all times.

To ensure that patients are able to maintain access to supplies of 300 microgram devices throughout this time we have asked Mylan to continue with their prescription validation process for pharmacies to order supplies of EpiPen 300 microgram. Further details are available at: www.epipen.co.uk.

Supplies of all 150 microgram devices (Emerade, Jext and EpiPen) are unaffected and remain available in volumes to support normal demand.

Send enquiries about this notice to the DH Supply Resilience Team supplyresiliencemd@dhsc.gov.uk quoting reference number SDA/2019/004.

To receive Supply Disruption Alerts directly from the Department of Health’s Central Alerting System (CAS) email: safetyalerts@mhra.gov.uk .



Posted in: ,


More Latest News >

CPCS Frequently Asked Questions

With the Community Pharmacist Consultation Service (CPCS) now bedding in, below you will find a selection of questions about the...

CPCS: CPD opportunities

As announced in the 5-year CPCF agreement, NHS England & NHS Improvement and Health Education England (HEE) will use funding...